RxDoctor Payments Data

Dennis Barnett, MD

Internal Medicine · Salem, ORNPI 1194097931

Payments from drug & device makers

$636in general payments, 2019–2025

Across 24 payments — averaging $26.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$198
  • Bayer$100
  • Pfizer$65
  • Boehringer Ingelheim$61
  • Impulse Dynamics (USA) Inc.$47
  • Novo Nordisk$37
  • plus $129 from 7 others

What the payments were for

  • Food & beverage$39963%
  • Education$23737%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$636 in reported general payments places this provider in the 85th percentile of 1,363 internal medicine providers in Oregon.

See all internal medicine providers in Oregon

Medicare billing

Part B allowed, 2024
$1,220
Medicare patients
11
Services billed
15

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide29$40,052
EliquisApixaban28$29,736
Lyumjev Kwikpen U-200Insulin Lispro-Aabc12$28,890
MounjaroTirzepatide26$26,472
JardianceEmpagliflozin23$25,382
MyrbetriqMirabegron32$14,608
RexultiBrexpiprazole12$14,302
TrulicityDulaglutide13$13,080
LinzessLinaclotide12$11,196
Eszopiclone22$2,957
Hydromorphone ErHydromorphone Hcl12$2,628
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen65$2,267
Semglee (Yfgn) PenInsulin Glargine-Yfgn11$2,258
Ramelteon14$2,033
Tolterodine Tartrate13$2,015

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$37$40,05229 claims
PfizerEliquis$65$29,73628 claims
Boehringer IngelheimJardiance$61$25,38223 claims
Astellas Pharma US IncMyrbetriq$198$14,60832 claims
Otsuka America Pharmaceutical, Inc.Rexulti$17$14,30212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,363 internal medicine providers in Oregon.

Other internal medicine in Salem

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →